Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luana Fianchi

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
American Journal of Blood Research|September 20, 2021
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormalityEsther N Oliva, Roberto Latagliata, Elena Sabattini, et al.
Journal of Clinical Medicine|November 9, 2024
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli StudyLuana Fianchi, Matteo Bonanni, Alessandra Borchiellini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 13, 2017
Treatment of Low-Blast Count AML using Hypomethylating AgentsEleonora De Bellis, Luana Fianchi, Francesco Buccisano, et al.
Annals of Hematology|June 28, 2018
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Alessandra Spagnoli, et al.
Blood Reviews|June 25, 2026
Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA groupFrancesco Marchesi, Corrado Girmenia, Enrico Maria Trecarichi, et al.
Journal of Hematology & Oncology|August 3, 2012
Outcome of therapy-related myeloid neoplasms treated with azacitidineLuana Fianchi, Marianna Criscuolo, Monia Lunghi, et al.
Hematological Oncology|May 4, 2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factorsAlessandro Andriani, Elena Elli, Giulio Trapè, et al.
American Journal of Hematology|July 19, 2016
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective surveyEnrico Maria Trecarichi, Livio Pagano, Bruno Martino, et al.
Annals of Hematology|April 20, 2016
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter studyFrancesco Buccisano, Anna Lina Piccioni, Carolina Nobile, et al.
British Journal of Haematology|July 30, 2022
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 studyVincenzo Marasco, Alfonso Piciocchi, Anna Candoni, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
American Journal of Blood Research|September 20, 2021
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormalityEsther N Oliva, Roberto Latagliata, Elena Sabattini, et al.
Journal of Clinical Medicine|November 9, 2024
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli StudyLuana Fianchi, Matteo Bonanni, Alessandra Borchiellini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 13, 2017
Treatment of Low-Blast Count AML using Hypomethylating AgentsEleonora De Bellis, Luana Fianchi, Francesco Buccisano, et al.
Annals of Hematology|June 28, 2018
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Alessandra Spagnoli, et al.
Blood Reviews|June 25, 2026
Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA groupFrancesco Marchesi, Corrado Girmenia, Enrico Maria Trecarichi, et al.
Journal of Hematology & Oncology|August 3, 2012
Outcome of therapy-related myeloid neoplasms treated with azacitidineLuana Fianchi, Marianna Criscuolo, Monia Lunghi, et al.
Hematological Oncology|May 4, 2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factorsAlessandro Andriani, Elena Elli, Giulio Trapè, et al.
American Journal of Hematology|July 19, 2016
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective surveyEnrico Maria Trecarichi, Livio Pagano, Bruno Martino, et al.
Annals of Hematology|April 20, 2016
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter studyFrancesco Buccisano, Anna Lina Piccioni, Carolina Nobile, et al.
British Journal of Haematology|July 30, 2022
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 studyVincenzo Marasco, Alfonso Piciocchi, Anna Candoni, et al.
Pageof 10